The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
MDSC; the Most Important Cell You Have Never Heard Of
Abstract
The myeloid-derived suppressor cell (MDSC) is the 'queen bee' of the tumor microenvironment. MDSCs protect the cancer from the patient's immune system, make the tumor resistant to immunotherapy, and allow the tumor to thrive while the patient withers away. Eliminating MDSCs should improve response rates to cancer therapy and patient survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myeloid-derived suppressor cells coming of age
Veglia, F., Perego, M., & Gabrilovich, D. (2018) · Nature Immunology · doi:10.1038/s41590-017-0022-x · Cited by 1,767
History of myeloid-derived suppressor cells
Talmadge, J. E., & Gabrilovich, D. I. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3581 · Cited by 1,148
Ugel, S., De Sanctis, F., Mandruzzato, S., & Bronte, V. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80006 · Cited by 559
Martens, A., Wistuba-Hamprecht, K., Foppen, M. G., Yuan, J., Postow, M. A., Wong, P., Romano, E., Khammari, A., Dreno, B., Capone, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2412 · Cited by 541
Fibroblasts in the Tumor Microenvironment: Shield or Spear?
Alkasalias, T., Moyano-Galceran, L., Arsenian-Henriksson, M., & Lehti, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051532 · Cited by 247
Tobin, R. P., Jordan, K. R., Robinson, W. A., Davis, D., Borges, V. F., Gonzalez, R., Lewis, K. D., & McCarter, M. D. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.08.007 · Cited by 204
The Role of Myeloid-Derived Suppressor Cells in Patients with Solid Tumors: A Meta-Analysis
Zhang, S., Ma, X., Zhu, C., Liu, L., Wang, G., & Yuan, X. (2016) · PLOS ONE · doi:10.1371/journal.pone.0164514 · Cited by 180
Antiinflammatory Therapy in Clinical Care: The CANTOS Trial and Beyond
Aday, A. W., & Ridker, P. M. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00062 · Cited by 143
Gonda, K., Shibata, M., Ohtake, T., Matsumoto, Y., Tachibana, K., Abe, N., Ohto, H., Sakurai, K., & Takenoshita, S. (2017) · Oncology Letters · doi:10.3892/ol.2017.6305 · Cited by 129
Inhibition of Soluble Tumor Necrosis Factor Prevents Chemically Induced Carcinogenesis in Mice
Sobo-Vujanovic, A., Vujanovic, L. N., DeLeo, A. B., Concha‐Benavente, F., Ferris, R. L., Lin, Y., & Vujanović, N. L. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0104 · Cited by 36
Move over Tregs, MDSCs are here
Semple, J. W. (2016) · Blood · doi:10.1182/blood-2016-01-692160 · Cited by 6
Cited by
Cancer vaccines as promising immuno-therapeutics: platforms and current progress
Liu, J., Fu, M., Wang, M., Wan, D., Wei, Y., & Wei, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01247-x · Cited by 715
Radiotherapy combined with immunotherapy: the dawn of cancer treatment
Zhang, Z., Liu, X., Chen, D., & Yu, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01102-y · Cited by 670
Drugging the efferocytosis process: concepts and opportunities
Mehrotra, P., & Ravichandran, K. S. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00470-y · Cited by 459
Tumor Immune Microenvironment during Epithelial–Mesenchymal Transition
Taki, M., Abiko, K., Ukita, M., Murakami, R., Yamanoi, K., Yamaguchi, K., Hamanishi, J., Baba, T., Matsumura, N., & Mandai, M. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4459 · Cited by 351
Ferroptosis in the tumor microenvironment: perspectives for immunotherapy
Xu, H., Ye, D., Ren, M., Zhang, H., & Bi, F. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.06.014 · Cited by 294
Metadata
- Authors
- Tesi, R. J.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2019-01
- Volume
- 40
- Issue
- 1
- Pages
- 4-7
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W2905436605
- Cited by
- 265
- References
- 11
- FWCI
- 7.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.